Related Experiment Video

Updated: May 19, 2026

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

The use of oncolytic viruses to overcome lung cancer drug resistance

Vladimir Beljanski1, John Hiscott

  • 1Vaccine and Gene Therapy Institute of Florida, 9801 Discovery Way, Port Saint Lucie, FL 34987, United States.

Current Opinion in Virology
|August 23, 2012
PubMed

Insights

Combining oncolytic viruses (OVs) with lung cancer treatments shows promise for overcoming drug resistance. These engineered viruses offer unique anti-tumor mechanisms and gene delivery capabilities, enhancing therapeutic efficacy.

Area of Science:

  • Oncology
  • Virology
  • Immunotherapy

Background:

  • Drug resistance is a major challenge in lung cancer treatment.
  • Conventional therapies often face intrinsic and acquired resistance.
  • Combining treatments is a key strategy to overcome resistance.

Purpose of the Study:

  • To explore the potential of oncolytic viruses (OVs) in overcoming lung cancer drug resistance.
  • To highlight the unique mechanisms of OVs compared to traditional chemotherapy.
  • To review promising combination strategies involving OVs and immunotherapy.

Main Methods:

  • Review of pre-clinical and clinical studies on oncolytic vaccines.
  • Analysis of OV mechanisms of action, including tumor cell lysis and gene delivery.
  • Evaluation of combination strategies to enhance oncolysis and circumvent resistance.

Main Results:

  • Oncolytic viruses (OVs) demonstrate unique tumor-killing mechanisms.
  • OVs can be engineered to deliver therapeutic or immunomodulatory genes.
  • Combination strategies involving OVs show promise in pre-clinical and clinical studies.
  • Studies indicate safety and efficacy of OVs in enhancing cancer therapy.

Conclusions:

  • Oncolytic viruses (OVs) represent a promising approach to combat lung cancer drug resistance.
  • Combining OVs with existing therapies can enhance treatment outcomes.
  • Further clinical trials are expected to solidify the role of OVs in lung cancer management.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...